Multisystem inflammatory syndrome in children (MIS-C) is a serious condition characterized
by excessive inflammation that can arise as a complication of SARS-CoV-2 infection in …

Abstract Background Multisystem Inflammatory Syndrome in Children (MIS-C), which occurs
2–6 weeks after initial exposure to SARS-CoV-2, was first identified in early 2020 when …

Background. There is limited information available regarding the management of
multisystem inflammatory syndrome in children (MIS‐C) associated with SARS‐CoV‐2. We …

Objective To determine the outcomes in children with MIS-C receiving different
immunomodulatory treatment. Methods In this multicentric, retrospective cohort study, data …

Background Multisystem inflammatory syndrome in children (MIS-C) is a severe disease
with an unpredictable course and a substantial risk of cardiogenic shock. Our objectives …

Background Evidence is urgently needed to support treatment decisions for children with
multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory …

Abstract Purpose of Review Different treatment approaches have been described for the
management of COVID-19-related multisystem inflammatory syndrome in children (MIS-C) …

Background Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory
condition associated with SARS-CoV-2 infection, has emerged as a serious illness in …

Background. To describe the existing pharmacological managements for Multisystem
Inflammatory Syndrome in Children (MIS-C) in a systematic way, to identify the available …

Multisystem inflammatory syndrome in children (MIS-C), also known as pediatric
inflammatory multisystem syndrome (PIMS), is a new postinfectious illness associated with …